Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE Study
Completed
- Conditions
- Hypertension
- Interventions
- Procedure: Home Blood Pressure
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 3554
- Registration Number
- NCT03254914
- Locations
- 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of
A Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: (fimasartan or linagliptin) x 7daysDrug: (fimasartan and linagliptin) x 7days
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 39
- Registration Number
- NCT03250052
- Locations
- 🇰🇷
Kyungpook National University Hospital, Seoul, Korea, Republic of
Fimasartan in the Senior Subjects
Phase 3
Completed
- Conditions
- The Elderly (≥ 70 Years) With Essential Hypertension
- Interventions
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 241
- Registration Number
- NCT03246555
- Locations
- 🇰🇷
Seoul National University Bundang, Seoul, Korea, Republic of
Fimasartan Blood Pressure Lowering After Acute Stroke
Completed
- Conditions
- Ischemic StrokeHypertensionTransient Ischemic Attack
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 1035
- Registration Number
- NCT03231293
- Locations
- 🇰🇷
Daejeon Eulji Medical Center, Daejeon, Korea, Republic of
🇰🇷Chonnam National University Hospital, Gwangju, Korea, Republic of
🇰🇷Korea University Ansan Hospital, Ansan, Korea, Republic of
A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet
Phase 1
Withdrawn
- Conditions
- Uterine Myoma
- Interventions
- Drug: BR-UPS 5 mg tablet, Inisia 5 mg tablet
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Registration Number
- NCT03156127
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia
Phase 3
Completed
- Conditions
- DyslipidemiaEssential Hypertension
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 138
- Registration Number
- NCT03156842
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin
Phase 1
Completed
- Conditions
- Hypertension, Hyperlipidemia
- Interventions
- Drug: Fimasartan/Amlodipine combination drug, Rosuvastatin
- First Posted Date
- 2016-12-16
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT02995720
A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Atorvastatin in Healthy Male Volunteers.
- First Posted Date
- 2016-12-16
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT02994745
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Compare the Safety and Pharmacokinetics of BR-TND Tablet(Tenofovir Disoproxil) With Viread Tablet(Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT02920931
- Locations
- 🇰🇷
ChungNam university hospital, ChungNam, Korea, Republic of
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Amlodipine in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Fimasartan/Amlodipine
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT02920047
© Copyright 2025. All Rights Reserved by MedPath